ibrutinib,rituximab
abbvie,janssen
[' ibru', 'cll', 'nhl', ' ave ', 'dlbcl']
triangle trial in mcl:
- med age 57, 3/4 male, ~96% adv stage
- r maintenance ~58% of each arm - ibr fixed 2 year duration
- modest improvement in crr w frontline addition of ibrutinib
- response assessment using ct, not pet (making comparison w other ph 2 trials fraught) #ash22 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer